16th congress of the European Association for Clinical Pharmacology and Therapeutics

Pathophysiology; drug discovery; mechanism of action; mechanism of toxicity; (epi)genetics of disease; target finding; lead optimization.

Modulation of the target; target engagement; animal or human models of disease; pharmacokinetics and drug metabolism; entry-into-human; human proof of mechanism and proof-of-concept.

Active-controlled clinical trials on drug efficacy and/or safety; trial methodology; regulatory sciences.

Patient-tailored pharmacotherapy; pharmacogenetics in drug efficacy and/or drug safety; drug-drug interaction; drug therapy in organ impairment; demographics and/or ethnicities in pharmacotherapy.

Drug therapy selection after passing Steps 1-4; cost-efficacy;  drug treatment guidelines; rational prescribing;  shared decision making; health technology assessment; therapeutic practices; formulary optimization; prescription review; learning healthcare.

Patient follow-up; (remote) monitoring of efficacy and safety; real world data; pharmacovigilance; therapeutic drug monitoring; compliance; treatment adaptation & optimization.